Analyst Ratings for [MNMD] Mind Medicine (MindMed) Inc.

1/28/25	Initiated	Outperform	X
MNMD MindMed Evercore ISI
$23
12/20/24	Initiated	Buy	X
MNMD MindMed Chardan Capital Markets
$20
10/14/24	Resumed	Outperform	X
MNMD MindMed Leerink Partners
$20
7/24/24	Initiated	Buy	X
MNMD MindMed ROTH MKM
$36
5/29/24	Initiated	Outperform	X
MNMD MindMed Robert W. Baird
$27
4/15/24	Initiated	Outperform	X
MNMD MindMed Leerink Partners
$20
12/5/23	Initiated	Buy	X
MNMD MindMed Canaccord Genuity
$9
12/9/22	Resumed	Buy	X
MNMD MindMed ROTH Capital
$25
11/16/22	Initiated	Outperform	X
MNMD MindMed RBC Capital Mkts
$5
8/26/22	Initiated	Outperform	X
MNMD MindMed Oppenheimer
$3.50
8/10/22	Initiated	Overweight	X
MNMD MindMed Cantor Fitzgerald
$3
5/4/22	Initiated	Buy	X
MNMD MindMed ROTH Capital
$7

MNMD Mind Medicine (MindMed) Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.